Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00335556 · OUTCOME

Event Free Survival Probability

Combination Chemotherapy, Radiation Therapy, and/or Surgery in Treating Patients With High-Risk Kidney Tumors · Source last updated 2017-07-21

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percent Probability 4 Year EFS
Interval / dispersion
95% Confidence Interval
Time frame
4 years

What was measured

Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610).

Analysis population: Eligible patients with Stage I focal and diffuse anaplastic Wilms tumor.

Groups in this outcome

Regimen DD-4A

Vincristine/dactinomycin/doxorubicin x25 weeks; XRT.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Regimen DD-4A18

Reported measurements

Source class 1
Values in Percent Probability 4 Year EFS · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Regimen DD-4A100.0Not reported100.0100.0Not reported

Source statistical analyses

Group order, estimate direction, methods and comments are retained. No treatment ranking is inferred.

  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The event-free survival distributions of patients with Stage I focal and diffuse anaplastic Wilms tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.
    group Ids
    1. OG000
    non Inferiority Type
    OTHER
    p Value
    .0570
    param Type
    Log Rank Test Statistic
    param Value
    3.6216
    statistical Method
    Log Rank
Complete source fields
analyses
  1. ci Num Sides
    TWO_SIDED
    ci Pct Value
    95
    group Description
    The event-free survival distributions of patients with Stage I focal and diffuse anaplastic Wilms tumors on AREN0321 and National Wilms Tumor Study-5 -- Treatment of Relapsed Patients, A National Wilms Tumor Study Group Phase III Study (NCT00002610) were compared using the log-rank test.
    group Ids
    1. OG000
    non Inferiority Type
    OTHER
    p Value
    .0570
    param Type
    Log Rank Test Statistic
    param Value
    3.6216
    statistical Method
    Log Rank
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        100.0
        upper Limit
        100.0
        value
        100.0
denoms
  1. counts
    1. group Id
      OG000
      value
      18
    units
    Participants
description
Event-free survival will be informally compared to that seem for similar patients treated on NWTS-5 (NCT00002610).
dispersion Type
95% Confidence Interval
groups
  1. description
    Vincristine/dactinomycin/doxorubicin x25 weeks; XRT.
    id
    OG000
    title
    Regimen DD-4A
param Type
NUMBER
population Description
Eligible patients with Stage I focal and diffuse anaplastic Wilms tumor.
reporting Status
POSTED
time Frame
4 years
title
Event Free Survival Probability
type
PRIMARY
unit Of Measure
Percent Probability 4 Year EFS

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice